News
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda
Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
EQS-Adhoc: BB Biotech AG publishes its 2023 annual report
EQS-Adhoc: BB Biotech AG publishes its 2023 annual report
EQS-News: Investor interest returns – dividend yield remains high for 2024
EQS-News: Investor interest returns – dividend yield remains high for 2024
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
COLTENE is optimistic for the future despite a challenging financial year 2023
COLTENE is optimistic for the future despite a challenging financial year 2023
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth